特发性肺纤维化合并晚期非小细胞肺癌的化疗疗效。
Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis.
机构信息
Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
出版信息
Respiration. 2013;85(4):326-31. doi: 10.1159/000342046. Epub 2012 Nov 21.
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for lung cancer in cases of IPF remains unknown.
OBJECTIVES
This study was conducted to elucidate the efficacy of chemotherapy for advanced non-small cell lung cancer (NSCLC) in patients with IPF.
METHODS
Advanced (i.e. stage IIIB and IV) NSCLC patients with IPF who received systemic chemotherapy were studied. Response rate, toxicity, overall survival and progression-free survival were investigated.
RESULTS
Between January 2000 and December 2009, 21 patients were enrolled in this study and treated with chemotherapy. The overall response rate with the 1st regimen was 42.9%. The median overall survival was 11.4 months, the 1-year survival rate was 28.6% and the median PFS was 5.4 months.
CONCLUSIONS
This study showed that advanced NSCLC patients with IPF may benefit from chemotherapy; well-controlled studies are still needed to clarify the efficacy.
背景
特发性肺纤维化（IPF）是最常见的特发性间质性肺炎类型，与肺癌发生的独立风险增加有关。IPF 患者肺癌的化疗获益仍不清楚。
目的
本研究旨在阐明化疗对 IPF 患者晚期非小细胞肺癌（NSCLC）的疗效。
方法
研究了接受全身化疗的 IPF 晚期（即 IIIB 期和 IV 期）NSCLC 患者。调查了反应率、毒性、总生存期和无进展生存期。
结果
2000 年 1 月至 2009 年 12 月期间，共纳入 21 例患者接受化疗。第 1 个方案的总体缓解率为 42.9%。中位总生存期为 11.4 个月，1 年生存率为 28.6%，中位无进展生存期为 5.4 个月。
结论
本研究表明，IPF 晚期 NSCLC 患者可能从化疗中获益；仍需要进行良好对照的研究来阐明疗效。
Zotero 插件